Already 3,608 people have seen this company's branding and they are being followed by 22 Storybook user.In average the company has been rated 4.3 points ja kommenteeritud 8 korda.

's activity report 2022

The main activity of TBD Pharmatech is fine chemistry and synthesis services and small-scale production of active pharmaceutical ingredients. The company's main customers are chemical, pharmaceutical and biotechnology companies in Europe, as well as in Switzerland and Israel.

The company has invested a lot in the design of its own product portfolio in recent years.

The company's product portfolio includes over 30 active pharmaceutical ingredients and fine chemical products.

TBD Pharmatech's sales revenue for 2022 was 5.17 million euros. The company's main income came from the provision of development services and the sale of portfolio products.

The profit for the 2022 financial year was 0.23 million euros.

In 2023, the company plans to continue providing development services and selling products. The company also plans to expand its operations in the coming years by building a new development and production complex

in Kambja parish, Tartu County. The construction project is currently being prepared.

Main financial ratios: 2022 2021

Revenue growth 6.75% 5.96%

Net profitability 4.54% 26.70%

Coverage ratio of short-term liabilities 4.89 6.42

ROA 3.94% 24.20%

ROE 4.64% 26.80% * Revenue growth (%) = (sales revenue 2022 - sales revenue 2021)/ sales revenue 2021 * 100 * Net profitability (%) = net profit/ sales revenue * 100 * Coverage ratio of short-term liabilities (times) = current assets/short-term liabilities * ROA (%) = net profit/ total assets * 100 * ROE (%) = net profit/ total equity * 100